Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Top
Summary
All studies
Cases
RCTs
Peer-reviewed
All outcomes

Feedback
Home   COVID-19 treatment studies for Iota-carrageenan  COVID-19 treatment studies for Iota-carragee..  C19 studies: Iota-carragee..  Iota-carragee..   Select treatmentSelect treatmentTreatmentsTreatments
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta
Lactoferrin Meta

Other Treatments Global Adoption
Outcomes in COVID-19 iota-carrageenan studies
0 0.5 1 1.5+ All studies 80% 1 394 Improvement, Studies, Patients Relative Risk Cases 80% 1 394 RCTs 80% 1 394 Prophylaxis 80% 1 394 Iota-carrageenan for COVID-19 c19early.org/g Dec 2022 Favorsiota-carrageenan Favorscontrol
0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 study c19early.org/g Dec 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 case result c19early.org/g Dec 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 Randomized Controlled Trials c19early.org/g Dec 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Prophylaxis 80% 0.20 [0.05-0.78] 2/196 10/198 80% improvement All studies 80% 0.20 [0.04-0.89] 2/196 10/198 80% improvement 1 iota-carrageenan COVID-19 peer reviewed trials c19early.org/g Dec 2022 Tau​2 = 0.00, I​2 = 0.0%, p = 0.035 Effect extraction pre-specified(most serious outcome) Favors iota-carrageenan Favors control 0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Figueroa (DB RCT) 80% 0.20 [0.05-0.78] symp. case 2/196 10/198 Improvement, RR [CI] Treatment Control Iota-carrageenan COVID-19 outcomes c19early.org/g Dec 2022 Favors iota-carrageenan Favors control
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit